The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the efficacy and safety of ketotifen (MC
stabilizer) on the basis of standard treatment after primary PCI in STEMI patients. The
ketotifen group and the control group were the ketotifen group and the control group. The
control group continued to receive STEMI standard treatment. The ketotifen group received
ketotifen for 3 months on the basis of standard treatment within 24 hours after primary PCI,
and was followed up for 1 year. Infarct size, as well as differences in echocardiography,
markers of two-dimensional speckle tracking, inflammatory factors and MC markers, and major
adverse cardiovascular events.